Answer first: Since the Unified Patent Court’s inauguration in June 2023, its jurisprudence has significantly influenced the European Patent Office’s approach to claim interpretation and validity. The EPO’s Enlarged Board of Appeal decision in G1/24 notably brought its standards closer to those of the UPC, fostering greater harmoni…
Patents context for IP teams
The Unified Patent Court (UPC), which commenced operations on 1 June 2023, has rapidly shaped European patent practice, particularly in the realm of claim interpretation under the European Patent Convention (EPC). Less than a year after its opening, the UPC Court of Appeal (CoA) issued a pivotal ruling in 10x Genomics vs. NanoString (UPC_CoA_335/2023), establishing a claim interpretation standard that diverged from the European Patent Office’s (EPO) traditional approach. This divergence prompted the EPO to reconsider its stance.
In June 2025, the EPO’s Enlarged Board of Appeal (EBoA) issued decision G1/24, explicitly aligning the EPO’s claim interpretation methodology more closely with that of the UPC. The EBoA underscored the unattractiveness of maintaining conflicting practices between the EPO and the judicial bodies responsible for adjudicating disputes downstream of granted patents. This marked a significant step toward harmonization, reflecting the EPO’s intent to synchronize its validity assessments with the UPC’s jurisprudence.
Key takeaways for EPO and UPC patent validity harmonization
- Confirm how the development affects patents ownership, enforcement, licensing, or portfolio records.
- Separate confirmed facts from legal interpretation before advising business teams.
- Map deadlines, affected assets, contracts, and evidence files to the responsible internal owner.
- Use the issue as a prompt for monitoring, filing strategy, dispute preparation, or member education.
Practical analysis
While harmonization is not a novel objective—the EBoA’s G5/83 decision from over four decades ago emphasized considering national courts’ and offices’ decisions within EPC Contracting States—it had limited practical effect on unifying standards. The recent G1/24 ruling, however, has catalyzed tangible progress, with the EPO adopting approaches that mirror UPC case law more closely. Conversely, the UPC’s evolving case law has also been influenced by established EPO validity principles, illustrating a reciprocal relationship.
The UPC’s initial reception was cautious; patent proprietors often opted out of the UPC system to avoid the risk of central revocation beyond the EPO’s nine-month opposition window. Potential claimants hesitated due to the lack of precedent and uncertainty regarding judgment quality. Nonetheless, by mid-2026, the UPC CoA had issued nearly 200 final decisions and orders, including approximately 30 substantive rulings on merits and preliminary injunctions. These decisions have addressed key validity issues such as claim interpretation, added matter, novelty, sufficiency, and inventive step.
Notably, the UPC’s bench includes European patent attorneys serving as technical judges, which has contributed to the jurisprudence’s resonance with EPO case law. Where divergences have emerged, such as in claim interpretation, the EPO has adjusted its practice to harmonize with the UPC’s approach.
This evolving jurisprudential landscape has practical implications for patent drafting and prosecution. For instance, the revised EPO approach to claim interpretation now generally accords definitions in the description “face value,” potentially overriding otherwise clear claim language. This necessitates careful drafting to avoid unintended claim scope consequences, particularly when incorporating definitions from the description into claims during prosecution.
Regarding inventive step, patentees may rely on a technical effect only if it is “encompassed by the technical teaching and embodied by the originally disclosed invention,” as established in G2/21. This standard applies uniformly before both the EPO and UPC. Although explicit disclosure of the technical effect in the original application is not mandatory, it is advisable to do so to ensure clarity and avoid misinterpretation. Additionally, reliance on post-filed data to demonstrate or confirm a technical effect depends on whether the effect falls within the scope of the originally disclosed invention.
Looking forward, the UPC’s seven-year opt-out period, which expires on 31 May 2030, will determine the extent to which European patents in UPC contracting states fall under the court’s jurisdiction. Should the opt-out not be extended, increased participation by sectors such as big pharma is anticipated, potentially influencing the development of UPC case law further.
While the UPC has provided clarity on many validity issues, certain areas remain underdeveloped, such as the court’s approach to the plausibility of therapeutic indications in sufficiency challenges—a frequent point of contention in pharmaceutical patent litigation. The evolution of jurisprudence in this domain will be closely watched.
This analysis is part four of a series examining the interplay between EPO and UPC approaches to patent validity, with prior installments exploring claim interpretation, added matter, novelty, sufficiency, and inventive step in greater detail.
The content herein serves as a general guide. Specific legal advice should be sought for individual circumstances.
Related IIPLA reading
EPO Aligns Patent Validity Standards with UPC Following Landmark Decisions Since the Unified Patent Court’s inauguration in June 2023, its jurisprudence has significantly influenced the European Patent Office’s approach to claim interpretation and validity. The EPO’s Enlarged Board of Appeal d... Read the full IIPLA blog post: https://iipla.org/blog/epo-aligns-patent-validity-standards-with-upc-following-landmark-decisions